Drug
Selinexor
Selinexor: highest development phase Phase 3, developed by Karyopharm Therapeutics, Roche, United Therapeutics. 34 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Karyopharm Therapeutics, Roche, United Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Selinexor NCT04562389 | Phase 3 | Myelofibrosis |
| Selinexor NCT05611931 | Phase 3 | Endometrial Cancer |
| Selinexor NCT05028348 | Phase 3 | Multiple Myeloma |
| Selinexor (combination therapy) NCT04442022 | Phase 2/3 | Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| Selinexor NCT04414475 | Phase 2 | Multiple Myeloma, Refractory |
| Selinexor NCT02227251 | Phase 2 | Diffuse Large B-cell Lymphoma |
| Selinexor NCT05597345 | Phase 2 | Smoldering Multiple Myeloma |
| Selinexor NCT01986348 | Phase 2 | Glioblastoma |
| Selinexor NCT03466827 | Phase 2 | Thymoma |
| Selinexor NCT03071276 | Phase 2 | Acute Myeloid Leukemia (AML) |
| Selinexor NCT02025985 | Phase 2 | Ovarian Carcinoma |
| Selinexor NCT05820763 | Phase 2 | Multiple Myeloma |
| Selinexor NCT04562870 | Phase 2 | Myelofibrosis |
| Selinexor 20 MG Oral Tablet NCT04717700 | Phase 2 | Multiple Myeloma |
| Selinexor NCT02628704 | Phase 2 | Multiple Myeloma |
| Selinexor NCT04843579 | Phase 2 | Myeloma Multiple |
| Selinexor 60 MG NCT04661137 | Phase 2 | Multiple Myeloma |
| Selinexor NCT04768881 | Phase 2 | Locally Advanced Unresectable or Metastatic Melanoma |
| Selinexor NCT02351505 | Phase 2 | Recurrent Small Cell Lung Carcinoma |
| selinexor (KPT-330) NCT02228525 | Phase 2 | Myelodysplastic Syndromes |
| Selinexor NCT02088541 | Phase 2 | Acute Myeloid Leukemia (AML) |
| Selinexor NCT02389543 | Phase 1/2 | Multiple Myeloma |
| Selinexor NCT02416908 | Phase 1/2 | Acute Myeloid Leukemia |
| Selinexor 100 mg NCT04256707 | Phase 1/2 | Non-Small Cell Lung Carcinoma (NSCLC) |
| Selinexor NCT03095612 | Phase 1/2 | Non-small Cell Lung Cancer |
| Selinexor NCT04421378 | Phase 1/2 | Glioblastoma Multiforme |
| Selinexor NCT02186834 | Phase 1/2 | Multiple Myeloma |
| Selinexor NCT02343042 | Phase 1/2 | Multiple Myeloma |
| selinexor NCT02120222 | Phase 1 | Recurrent Melanoma |
| Selinexor NCT03042819 | Phase 1 | Soft Tissue Sarcoma |
| Selinexor NCT07200102 | Phase 1 | Multiple Myeloma |
| selinexor NCT02741388 | Phase 1 | B-cell Lymphoma |
| Selinexor NCT04984330 | Phase 1 | Amyloid |
| Selinexor NCT01607905 | Phase 1 | Solid Tumor |
Latest
No recent events.
Follow Selinexor on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.